Daily Stock Analysis, ABIO, ARCA Biopharma Inc, priceseries

ARCA Biopharma Inc. Daily Stock Analysis
Stock Information
Open
6.85
Close
7.14
High
7.14
Low
6.79
Previous Close
6.90
Daily Price Gain
0.24
YTD High
20.45
YTD High Date
May 2, 2019
YTD Low
5.01
YTD Low Date
Apr 30, 2019
YTD Price Change
1.20
YTD Gain
20.20%
52 Week High
23.04
52 Week High Date
Jul 31, 2018
52 Week Low
4.72
52 Week Low Date
Dec 28, 2018
52 Week Price Change
-3.16
52 Week Gain
-30.70%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 3. 2018
26.10
Jan 17. 2018
28.08
9 Trading Days
7.58%
Link
LONG
May 8. 2018
9.47
May 29. 2018
10.38
14 Trading Days
9.68%
Link
LONG
Jul 10. 2018
10.47
Jul 11. 2018
11.00
1 Trading Days
5.01%
Link
LONG
Sep 28. 2018
10.08
Oct 8. 2018
11.81
6 Trading Days
17.16%
Link
LONG
Mar 4. 2019
8.28
Mar 6. 2019
9.09
2 Trading Days
9.78%
Link
LONG
May 7. 2019
12.58
May 10. 2019
13.21
3 Trading Days
5.01%
Link
Company Information
Stock Symbol
ABIO
Exchange
NasdaqCM
Company URL
http://www.arcabiopharma.com
Company Phone
720-940-2200
CEO
Michael R. Bristow
Headquarters
Colorado
Business Address
11080 CIRCLEPOINT ROAD, SUITE 140, WESTMINSTER, CO 80020
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0000907654
About

ARCA biopharma, Inc. is a biopharmaceutical company, which develops genetically targeted therapies for heart failure and other cardiovascular diseases. The company's business combines expertise in cardiovascular pathophysiology, molecular genetics and clinical development. Its product candidate, GencaroTM is a pharmacologic beta-blocker and mild vasodilator, which is developed for the treatment of chronic heart failure and other indications. The company was founded by Michael R. Bristow and Christopher David Ozeroff in 1992 and is headquartered in Westminster, CO.

Description

ARCA biopharma, Inc., a biopharmaceutical company, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically beta-blocker and mild vasodilator, which is in clinical trial for the treatment of atrial fibrillation in patients with heart failure and left ventricular with reduced left ventricular ejection fraction. The company also engages in developing recombinant Nematode Anticoagulation Protein c2, a therapy for the disease syndrome caused by infection from hemorrhagic fever viruses and other pathogens. The company has a collaboration agreement with Medtronic, Inc. for the support of GENETIC-AF Phase 2B/Phase 3 clinical trials; and Laboratory Corporation of America to provide the companion diagnostic test and services to support GENETIC-AF trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.